Screening and management of portal hypertension and varices in cirrhosis: Expert perspectives.

IF 5.6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Hepatology Communications Pub Date : 2025-04-03 eCollection Date: 2025-04-01 DOI:10.1097/HC9.0000000000000682
Robert S Brown, Kimberly A Brown, Steve Flamm, Rachel E Bejarano, Robert S Rahimi, Ashwani K Singal, Don C Rockey
{"title":"Screening and management of portal hypertension and varices in cirrhosis: Expert perspectives.","authors":"Robert S Brown, Kimberly A Brown, Steve Flamm, Rachel E Bejarano, Robert S Rahimi, Ashwani K Singal, Don C Rockey","doi":"10.1097/HC9.0000000000000682","DOIUrl":null,"url":null,"abstract":"<p><p>The prevalence of liver injury, fibrosis, and, in particular, cirrhosis in the United States is increasing in parallel to the current epidemic of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. As fibrosis advances, portal hypertension occurs, and when the pressure gradient meets or exceeds 10 mm Hg, the patient is at an increased risk for decompensating events such as esophageal varices. The risk of death also increases. Therefore, decreasing the risk of progression to decompensated cirrhosis is an important management goal. The American Association for the Study of Liver Diseases recently published a guidance document to \"coalesce best practice recommendations for the identification of portal hypertension, for prevention of initial hepatic decompensation, for the management of acute variceal hemorrhage, and for reduction of the risk of recurrent variceal hemorrhage in chronic liver disease.\" In this updated guidance, the new terms \"advanced chronic liver disease\" and \"clinically significant portal hypertension\" have been proposed for routine use in clinical practice. Following recommendations for advanced chronic liver disease identification, which are largely defined by transient elastography measurements of liver stiffness, guidance is provided on the identification of clinically significant portal hypertension and early administration of nonselective beta-blocker therapy in clinically significant portal hypertension for prophylaxis. Optimal control of active bleeding, the role of preemptive TIPS, and gastric varices management are also addressed. Despite the wealth of information provided, the guidance can be difficult to put into practice, leaving non-liver-focused clinicians with an unmet need for a simplified approach to guidelines in general. To address this issue, a panel of hepatologists met to review and discuss the real-world implications of this new guidance and the result is this expert perspective review. This review aims to facilitate improvements in risk stratification and management of variceal bleeding, streamline controversial and complex issues in the recent guidance in a practical way for clinical use, and make recommendations on how to incorporate this important new guidance document into clinical practice.</p>","PeriodicalId":12978,"journal":{"name":"Hepatology Communications","volume":"9 4","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970884/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Communications","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/HC9.0000000000000682","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The prevalence of liver injury, fibrosis, and, in particular, cirrhosis in the United States is increasing in parallel to the current epidemic of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. As fibrosis advances, portal hypertension occurs, and when the pressure gradient meets or exceeds 10 mm Hg, the patient is at an increased risk for decompensating events such as esophageal varices. The risk of death also increases. Therefore, decreasing the risk of progression to decompensated cirrhosis is an important management goal. The American Association for the Study of Liver Diseases recently published a guidance document to "coalesce best practice recommendations for the identification of portal hypertension, for prevention of initial hepatic decompensation, for the management of acute variceal hemorrhage, and for reduction of the risk of recurrent variceal hemorrhage in chronic liver disease." In this updated guidance, the new terms "advanced chronic liver disease" and "clinically significant portal hypertension" have been proposed for routine use in clinical practice. Following recommendations for advanced chronic liver disease identification, which are largely defined by transient elastography measurements of liver stiffness, guidance is provided on the identification of clinically significant portal hypertension and early administration of nonselective beta-blocker therapy in clinically significant portal hypertension for prophylaxis. Optimal control of active bleeding, the role of preemptive TIPS, and gastric varices management are also addressed. Despite the wealth of information provided, the guidance can be difficult to put into practice, leaving non-liver-focused clinicians with an unmet need for a simplified approach to guidelines in general. To address this issue, a panel of hepatologists met to review and discuss the real-world implications of this new guidance and the result is this expert perspective review. This review aims to facilitate improvements in risk stratification and management of variceal bleeding, streamline controversial and complex issues in the recent guidance in a practical way for clinical use, and make recommendations on how to incorporate this important new guidance document into clinical practice.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Hepatology Communications
Hepatology Communications GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
8.00
自引率
2.00%
发文量
248
审稿时长
8 weeks
期刊介绍: Hepatology Communications is a peer-reviewed, online-only, open access journal for fast dissemination of high quality basic, translational, and clinical research in hepatology. Hepatology Communications maintains high standard and rigorous peer review. Because of its open access nature, authors retain the copyright to their works, all articles are immediately available and free to read and share, and it is fully compliant with funder and institutional mandates. The journal is committed to fast publication and author satisfaction. ​
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信